Erasmus University Rotterdam (EUR)
Browse

Patient-relevance of outcome measures in breast cancer clinical trials - Data Files

dataset
posted on 2025-03-27, 14:12 authored by Diana DelnoijDiana Delnoij, Jasmijn Plooij
<p dir="ltr">The primary research question for which these data have been used, was: ‘How patient-relevant are outcomes measured in clinical trials for breast cancer drugs?’. Subquestions were: 1. Which treatment outcomes are relevant for breast cancer patients? 2. Which outcome measures are used in clinical trials for breast cancer drugs? 3. How much overlap is there between patient-relevant outcomes and outcomes measured in clinical trials?</p><p dir="ltr">The dataset has been used to answer subquestion 2. Data have been obtained by searching Clinicaltrials.gov for trials conducted between January 2014 and March 2024 inclusive. Further inclusion criteria were that studies had to be phase III trials and had to focus on breast cancer, adults (18-64 years old) and drugs. Interventions focusing on lifestyle changes, Chinese medicine, anaesthesia, surgery and diagnostic methods were excluded. Ultimately, 264 trials were included and forty-five excluded. To determine the outcome measures used, the study plan of every included trial was reviewed and recorded on the data sheet.</p>

Funding

No funding was received

History

Encoding format

  • Choose an encoding format
  • ODS
  • PDF/A
  • TXT

Content size

5.26MB

Conditions of access

  • Open access

Language

English

Temporal coverage

2014-01-01/2024-03-31

Spatial coverage

Worldwide

Universe

Clinicaltrials.gov

Analysis unit

Breast Cancer Clinical Studies for Participants Aged 18 to 64.

Does your data contain sensitive data

  • No

Usage metrics

    Erasmus School of Health Policy & Management

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC